Besifloksacin
 | |
| Klinički podaci | |
|---|---|
| Drugs.com | Monografija |
| Način primene | Oftalmički |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 7 h |
| Izlučivanje | N/A |
| Identifikatori | |
| CAS broj | 141388-76-3  Y |
| ATC kod | S01AE08 (WHO) |
| PubChem | CID 10178705 |
| DrugBank | DB06771 Y |
| ChemSpider | 8354210 Y |
| ChEMBL | CHEMBL1201760 Y |
| Hemijski podaci | |
| Formula | C19H21ClFN3O3 |
| Molarna masa | 393,840 |
SMILES
| |
InChI
| |
Besifloksacin je organsko jedinjenje, koje sadrži 19 atoma ugljenika i ima molekulsku masu od 393,840 Da.[1][2][3][4]
Osobine
| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 6 |
| Broj donora vodonika | 2 |
| Broj rotacionih veza | 3 |
| Particioni koeficijent[5] (ALogP) | 0,3 |
| Rastvorljivost[6] (logS, log(mol/L)) | -4,0 |
| Polarna površina[7] (PSA, Å2) | 86,9 |
Reference
- ^ O'Brien TP: Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. Adv Ther. 2012 Jun;29(6):473-90. doi: 10.1007/s12325-012-0027-7. Epub 2012 Jun 20. PMID 22729919
- ^ Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW: Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009 Aug;25(4):335-44. doi: 10.1089/jop.2008.0116. PMID 19492955
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126. - ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
- Besifloxacin
- p
- r
- u
(inhibira
purinski metabolizam,
i tim putem inhibira
DNK i RNK sintezu)
| DR inhibitor | |||||||
|---|---|---|---|---|---|---|---|
| Sulfonamidi (DS inhibitor) |
| ||||||
| Drugi/negrupisani | |||||||
| Kombinacije |
topoizomeraze/
hinoloni/
(inhibiraju
DNK replikaciju)
| 1. generacija | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fluorohinoloni |
|
inhibitori
| Nitro- imidazol derivati | |
|---|---|
| Nitrofuran derivati |
| Rifamicinii/ RNK polimeraza |
|---|
| |||||
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
Besifloksacin na srodnim projektima Vikipedije:
Mediji na Ostavi
Podaci na Vikipodacima
